Chemomab <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures FDA Alignment on CMC and Toxicology Milestones, Advancing Phase 3 Development of Nebokitug for PSC
TEL AVIV, Israel, June 11, 2025 -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced positive feedback from two recent meetings with the FDA, facilitating the advancement of their drug nebokitug into a Phase 3 clinical trial for Primary Sclerosing Cholangitis $(PSC.AU)$. The FDA has aligned with Chemomab on essential Chemistry, Manufacturing, and Controls $(CMC)$ requirements, ensuring the quality and consistency of the drug supply, and has also agreed to allow non-clinical toxicology studies to proceed concurrently with the Phase 3 clinical trial. This regulatory progress supports the timely advancement of nebokitug's development program as Chemomab continues discussions with potential strategic partners.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466553-en) on June 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。